Medtronic Plc

Latest Medtronic Plc News and Updates

  • uploads///eps
    Earnings Report

    What to Expect from St. Jude Medical’s Earnings in 2Q16

    In 1Q16, St. Jude Medical exceeded analysts’ EPS (earnings per share) estimate of $0.89 as well as the revenue estimate of ~$1.4 billion.

    By Sarah Collins
  • Healthcare

    Farallon Capital adds a new position in Covidien

    Ireland-based Covidien is a global healthcare leader that offers innovative medical technology solutions and patient care products to providers.

    By Patricia Garner
  • uploads///Chart
    Earnings Report

    What Does Johnson & Johnson Predict for Its Medical Devices Segment?

    Johnson & Johnson’s (JNJ) medical devices segment deals with vision care, cardiovascular care, specialty surgery, orthopedics, surgical care, and diabetes care.

    By Mike Benson
  • uploads///revenue estimates
    Earnings Report

    Will Medtronic Maintain Its Revenue Growth Momentum in Fiscal 1Q18?

    In fiscal 1Q18, Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.45 billion, which represents a rise of ~4% in comparison to its fiscal 1Q17 revenue of $7.17 billion.

    By Sarah Collins
  • uploads///REVENUE ESTIMATES
    Earnings Report

    Analysts Expect Medtronic’s Revenue to Rise 4% in Fiscal 4Q17

    Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.9 billion in fiscal 4Q17, a rise of ~4% compared to its fiscal 4Q16 revenue of $7.6 billion.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    How Has Medtronic’s Stock Performed Recently?

    Medtronic (MDT) was trading at $80.3 on November 15, 2016. It had a 50-day moving average of $83.7 and a 200-day moving average of $84.8.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    A Look at Boston Scientific’s Valuation Multiples in September

    On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.

    By Sarah Collins
  • uploads///diabetes _
    Company & Industry Overviews

    Tandem Diabetes Care Rallies on FDA Approval of Insulin Pump

    Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology.

    By Sarah Collins
  • uploads///revenue estimates
    Earnings Report

    Medtronic’s Revenue Is Estimated to Rise in Fiscal 2Q17

    On November 22, 2016, Medtronic (MDT) will announce its fiscal 2Q17 earnings for the period that ended on October 31, 2016.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results

    On January 29, 2018, Abbott Laboratories (ABT) closed trading at $63.31 per share. The company reported its 52-week high of $64.60 on January 25.

    By Sarah Collins
  • uploads///animas exit from insulin pump business
    Company & Industry Overviews

    Tandem Diabetes Care’s International Expansion Strategy

    Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.

    By Sarah Collins
  • uploads///piron guillaume  unsplash
    Earnings Report

    Analysts Raise Target Prices on ABT ahead of Q3 Earnings

    Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.

    By Sarah Collins
  • uploads///DIABETES
    Earnings Report

    What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17?

    Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.

    By Sarah Collins
  • uploads///CASH FLOW
    Company & Industry Overviews

    How Tax Reform Affected Medtronic’s 3Q18 Performance

    Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]

    By Sarah Collins
  • uploads///minimed g launch dynamics
    Company & Industry Overviews

    Diabetes Management Breakthrough: Medtronic’s MiniMed 670G

    On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.

    By Sarah Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    Allergan Boosts XLV Large-Caps with Positive 4Q15 Earnings

    Allergan (AGN) reported its 4Q15 earnings on February 22, 2016. It reported net revenue of $4.2 billion for 4Q15, an increase of 74% compared to $2.4 billion in 4Q14.

    By Peter Neil
  • uploads///
    Miscellaneous

    Fitbit’s Team Strategy: The Benefits of Acquisitions and Partnerships

    In 2016, Fitbit (FIT) inked a deal with Pebble to harvest certain Pebble assets, now that the latter company has begun shutting down operations.

    By Adam Rogers
  • uploads///aid __
    Company & Industry Overviews

    Boston Scientific Expands Its Endoscopy Business with EMcision Acquisition

    On March 5, 2018, Boston Scientific (BSX) announced the acquisition of EMcision, which will expand the company’s endoscopy business.

    By Sarah Collins
  • uploads///minimed g
    Company & Industry Overviews

    Medtronic’s Key Growth Driver: MiniMed 670G Hybrid Closed Loop

    Medtronic’s Diabetes Group performance in fiscal Q4 2018 was driven by a 25% growth for its MiniMed 670G hybrid closed-loop insulin pump.

    By Sarah Collins
  • uploads///thv
    Earnings Report

    What Led to Edwards Lifesciences’ Stellar Performance in 1Q16?

    Edwards Lifesciences (EW) reported ~$697 million in total revenue in 1Q16. Of that, ~$366 million was contributed by the company’s THV (Transcatheter Heart Valve) Therapy segment.

    By Sarah Collins
  • uploads///share price on Oct
    Earnings Report

    ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade

    On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close.

    By Sarah Collins
  • uploads///hush naidoo  unsplash
    Earnings Report

    Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results

    Edwards Lifesciences is set to release its third-quarter earnings results after the market closes on October 23. Let’s see what to expect.

    By Sarah Collins
  • uploads///diabetes _
    Earnings Report

    Analysts’ Recent Recommendations and Target Price for ABT Stock

    On May 2, a Reuters survey noted that of 20 brokerage firms tracking Abbott Laboratories, 16 analysts recommended a “buy” or a “strong buy.”

    By Sarah Collins
  • uploads///eps estimates
    Earnings Report

    Will Medtronic Meet Analysts’ Earnings Estimates in Fiscal 1Q18?

    For the last several quarters, Medtronic has consistently exceeded analysts’ earnings estimates.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Tandem Diabetes Care’s Stock Performance This Month

    On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump.

    By Sarah Collins
  • uploads///stock performance
    Earnings Report

    Abbott Laboratories’ Stock Price Performance in July

    Year-to-date, ABT stock has risen 12.8%. Over the last month, the stock has returned ~4.0%.

    By Sarah Collins
  • uploads///hush naidoo  unsplash
    Company & Industry Overviews

    Trade War Fears Triggered Medtronic’s Stock Decline on March 23

    Following heightened concerns of a US–China trade war, Medtronic (MDT) stock hit its 52-week low of $76.41 on March 23, 2018.

    By Sarah Collins
  • uploads///mitg segment performance
    Company & Industry Overviews

    Innovative Products Driving Medtronic’s Growth

    Medtronic expects its MITG segment to have an organic growth rate of 4% in fiscal 2019.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    How Has Boston Scientific Stock Performed Recently?

    Boston Scientific (BSX) was trading at $27.9 on June 29, 2017.

    By Sarah Collins
  • uploads///innovation strategies
    Company & Industry Overviews

    How Johnson & Johnson’s Partnerships Enhance Customer Value

    Johnson & Johnson’s key innovation strategies include creating value through strategic customer partnerships and solutions.

    By Sarah Collins
  • uploads///hospital _
    Earnings Report

    Analysts’ Views on Abbott Laboratories before Q2 2018 Earnings

    On July 18, Abbott Laboratories (ABT) is expected to release its earnings results for its fiscal second quarter of 2018.

    By Sarah Collins
  • uploads///hand __
    Company & Industry Overviews

    BSX Stock Regains Momentum after Its Recent Bearish Trend

    On February 14, 2018, Boston Scientific stock closed the day at $26.81. The stock was trading near its 50-day moving average of $26.82.

    By Sarah Collins
  • uploads///revenue estimates
    Company & Industry Overviews

    Stryker’s Recent Stock Price Movement: Upside Potential?

    Stryker stock has registered slightly volatile activity in the past few months. However, the stock largely remains on a bullish trajectory.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    A Look at Medtronic’s Recent Stock Performance

    Medtronic (MDT) was trading at $83.9 on May 22, 2017. It had a 50-day moving average of $82.1 and a 200-day moving average of $78.4.

    By Sarah Collins
  • Healthcare

    Must-know: Key export barriers for medical device manufacturers

    Most large U.S. manufacturers have invested significant capital into emerging markets, including Medtronics, Johnson & Johnson, GE, and Stryker.

    By Amritpal Khalsa
  • uploads///hospital _
    Company & Industry Overviews

    Boston Scientific Stock in the Week Ended September 14

    Today, Boston Scientific (BSX) opened at $37.43, down ~0.51% compared to yesterday’s closing price of $37.62.

    By Sarah Collins
  • uploads///watson
    Company & Industry Overviews

    IBM Is Paving the Way for Watson Health: Acquisitions and Deals

    IBM’s partnership with Apple is especially appealing. Watson Health will bring cloud services and analytics to Apple’s HealthKit and ResearchKit.

    By Anne Shields
  • uploads///analyst recommendations
    Company & Industry Overviews

    Wall Street Maintains ‘Strong Buy’ Recommendation for Stryker

    Analysts’ recommendations Stryker (SYK) has registered strong results over the last few quarters and has been expanding at a fast pace through organic and inorganic growth. The company has made a number of acquisitions and expanded its market presence across product lines and regions. Its most recent earnings results were reported on October 26, 2017. For details, read […]

    By Sarah Collins
  • uploads///geographic strength
    Company & Industry Overviews

    How BD-Bard Acquisition Will Strengthen International Presence

    C.R. Bard (BCR) has grown significantly outside the United States in recent years, driven by its international channel expansion strategy.

    By Sarah Collins
  • uploads///medical device segment
    Company & Industry Overviews

    Abbott’s Freestyle Libre Gets Reimbursement Approval in France

    Abbott Laboratories’ (ABT) Freestyle Libre is a sensor-based continuous glucose monitoring system that monitors and evaluates glucose levels up to 14 days.

    By Sarah Collins
  • uploads///key strategies
    Company & Industry Overviews

    Understanding Zimmer Biomet’s Latest Dividend Announcement

    On December 18, 2017, Zimmer Biomet Holdings (ZBH) announced a quarterly cash dividend of $0.24 per share for fiscal 4Q17.

    By Sarah Collins
  • uploads///TWC CMCSA
    Technology & Communications

    Must-know: Is the Time Warner Cable–Comcast deal a “do?”

    Arbs generally avoid utility deals—and for good reason. Typically, the companies have an aggressive expected timeline and these deals don’t close on time.

    By Brent Nyitray, CFA, MBA
  • uploads///valuation
    Earnings Report

    Abbott Laboratories’s Valuation before Its 2Q16 Results

    After the release of its 1Q16 earnings results on April 20, 2016, Abbott Laboratories (ABT) was trading at a forward PE multiple in the range of 16.4x–19.3x.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    Understanding JNJ’s Latest Stock Price Rise

    On July 20, 2017, JNJ stock was trading at its 52-week high of $137.1, which was ~25.4% above its 52-week low of $109.3 on December 7, 2016.

    By Sarah Collins
  • uploads///highlights
    Company & Industry Overviews

    Behind JNJ’s Recent Stock Price Performance: Is More Growth Coming?

    Johnson & Johnson (JNJ) has seen a few disappointing quarterly performances, but on October 17, when JNJ announced its 3Q17 results, the stock gained 3.4%.

    By Sarah Collins
  • Industrials

    Brazil’s medical device industry: Health coverage outlook

    The upward trends of the healthcare market show that Brazil is positive for the medical device industry, suggesting rapid increases in demand as more and more people can afford the devices and pay accordingly.

    By Amritpal Khalsa
  • uploads///eps estimates
    Earnings Report

    What Can We Expect for Stryker’s Earnings in 2Q16?

    In 1Q16, Stryker exceeded analysts’ EPS (earnings per share) estimate of $1.20, as well as the revenue estimate of ~$2.5 billion.

    By Sarah Collins
  • uploads///medic _
    Healthcare

    Abbott Laboratories Posted Its Q1 Earnings, Stock Rose 4%

    At 10:07 AM ET today, Abbott Laboratories (NYSE:ABT) stock rose by about 3.9%. The company reported its first-quarter financial results.

    By Ambrish Shah
  • uploads///laboratory _
    Healthcare

    Abbott’s Q1 Earnings Report Might Boost Its Stock

    Abbott Laboratories (NYSE:ABT) stock rose by about 1.0% in extended trading on Thursday. The stock rose 1.3% and closed at $86.04.

    By Ambrish Shah
  • uploads///wall street _
    Fund Managers

    D.E. Shaw & Co.: Where Is David Shaw Bullish?

    At the end of Q3 2019, D.E. Shaw & Co.’s total portfolio of publicly traded securities was worth around $81.2 billion.

    By Rabindra Samanta
  • uploads///CALPERS positions
    Energy & Utilities

    Highlights of CalPERS holdings in 4Q14

    CalPERS noted that it has recovered approximately $900 million to date from settlements related to investment losses sustained during the financial crisis.

    By Samantha Nielson
  • uploads///stock picture HJHQsQohM
    Consumer

    Wellington Management: Analyzing Its Top Holdings

    Wellington Management filed its 13F on Wednesday. Based on the filing, the market value of total publicly traded securities was around $443.45 billion.

    By Rabindra Samanta
  • uploads///Puerto Ricos GDB Economic Activity Index
    Healthcare

    Must-know market update: Is Puerto Rico losing its salsero vibe?

    The charm of the island has been overshadowed with feelings of pessimism regarding the fiscally distressed state of the economy.

    By Surbhi Jain
  • uploads///bence boros anapPhJFRhM unsplash
    Company & Industry Overviews

    Amazon Partners with over 30 Companies: VI Initiative

    On September 24, Amazon (AMZN) announced the Voice Interoperability Initiative. The announcement was one day before the Amazon hardware event.

    By Shankar Iyer
  • uploads///ABT STJ product portfolio
    Company & Industry Overviews

    These Developments Impacted Abbott Laboratories the Most in Fiscal 2017

    Abbott Laboratories posted a strong earnings results on January 24, surpassing Wall Street estimates and posting earnings at the high end of its guidance.

    By Sarah Collins
  • uploads///Pfizer stock
    Company & Industry Overviews

    Why Pfizer Stock Continues to Tank after Mylan Deal

    Pfizer stock (PFE) has fallen 10% in the past two days on its deal with Mylan (MYL) and its lower earnings guidance.

    By Maitali Ramkumar
  • uploads///Graph
    Earnings Report

    What Is Medtronic Guiding for Its Business Segments in 2020?

    In the fourth quarter, Medtronic’s spine business reported revenue of $691 million, a YoY fall of 1.1% on a reported basis.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Emerging Markets: Medtronic’s Key Revenue Driver in 2019

    In the fourth quarter, Medtronic earned revenue of $4.28 billion in the US market, a YoY (year-over-year) rise of 2.3% on a reported and constant-currency basis.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Medtronic Guides for Robust Free Cash Flow Conversion for 2020

    During its 2018 Investor Day presentation, Medtronic (MDT) set a target of 80% FCF (free cash flow) conversion.

    By Margaret Patrick
  • uploads///MDT RTG
    Company & Industry Overviews

    How Did Medtronic’s Restorative Therapies Group Perform?

    Medtronic’s (MDT) Spine Therapies generated revenues of $1.3 billion in the first half of fiscal 2019.

    By Daniel Collins
  • uploads///MITG
    Company & Industry Overviews

    How Medtronic’s Minimally Invasive Therapies Group Has Performed

    Medtronic’s MITG segment generated revenues of $4.1 billion in the first half of fiscal 2019 compared to $4.4 billion in the first half of fiscal 2018.

    By Daniel Collins
  • uploads///MDTs CVG
    Company & Industry Overviews

    A Look at Medtronic’s Cardiac & Vascular Group’s Revenue Streams

    Medtronic’s (MDT) Cardiac Rhythm & Heart Failure segment generated revenues of $1.47 billion in the second quarter of fiscal 2019.

    By Daniel Collins
  • uploads///MDT net income
    Company & Industry Overviews

    A Look at Medtronic’s Earnings Trends and Guidance for Fiscal 2019

    Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018.

    By Daniel Collins
  • uploads///analysis _
    Company & Industry Overviews

    How Wall Street Analysts View Medtronic in December

    Of the 27 analysts tracking Medtronic in December 2018, six of them recommended a “strong buy,” while nine analysts recommended a “buy.”

    By Daniel Collins
  • uploads///AI market shares
    Company & Industry Overviews

    How IBM Is Investing in AI Solutions

    AI is the buzzword these days, and the market has huge growth potential.

    By Puneet Sikka
  • uploads///Chart
    Earnings Report

    Sanofi: Analysts’ Recommendations on October 30

    As of October 30, four analysts are tracking Sanofi. Two analysts recommend a “strong buy,” while two analysts recommend a “hold.”

    By Mike Benson
  • Why Morningstar Is Overweight on Healthcare
    Healthcare

    Why Morningstar Is Overweight on Healthcare

    As the third graph shows, the Morningstar US Wide Moat Focus Index has over a 30% weight in healthcare, while the S&P 500 Index has only a 15% weight in the sector.

    By VanEck
  • uploads///lab _
    Earnings Report

    Thermo Fisher Beats Analysts’ Estimates in Q3 2018 Earnings

    Thermo Fisher Scientific (TMO) reported its third-quarter results today. It surpassed analysts’ estimates for EPS and revenue.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Thermo Fisher’s Third-Quarter Revenue Estimates

    The Life Sciences Solutions segment, including reagents, instruments, and consumables, contributes ~25% of Thermo Fisher’s total revenues.

    By Mike Benson
  • uploads///ISRG RD
    Earnings Report

    How Intuitive’s Bottom Line Is Expected to Look in Q3 2018

    Intuitive Surgical’s (ISRG) cost of goods sold is expected to rise 16.82% to $265.76 million in the third quarter of 2018.

    By Kenneth Smith
  • uploads///STOCK PRICE
    Company & Industry Overviews

    ABT Stock Registered a 52-Week High in October

    On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    How GlaxoSmithKline’s Pharmaceutical Business Performed

    GlaxoSmithKline’s (GSK) Pharmaceutical segment includes various products from different therapeutic areas including respiratory products, HIV products, immuno-inflammation products, and established products.

    By Mike Benson
  • uploads///COMPARISON
    Company & Industry Overviews

    EW Stock Returned More than the S&P 500’s Gain in 2018

    As of September 28, Edwards Lifesciences (EW) has registered a rise of ~52.5% YTD (year-to-date). In the same period, the S&P 500 has risen ~9.2%.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    High Valuation Multiples: Is EW Stock an Expensive Bet?

    On September 27, Edwards Lifesciences was trading at a forward PE multiple of 33.2x, while its trailing 12-month PE multiple was 39.3x.

    By Sarah Collins
  • uploads///VRAY ana reco
    Company & Industry Overviews

    What ViewRay’s Valuation Trend Indicates

    In September, of the seven analysts covering ViewRay (VRAY), six have given its stock “buy” or higher ratings, and one analyst has given it a “sell” rating.

    By Kenneth Smith
  • uploads///A ana reco
    Company & Industry Overviews

    What’s the Upside Potential for Agilent Technologies Stock?

    In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018.

    By Kenneth Smith
  • uploads///COMPARISON
    Company & Industry Overviews

    ABT Returns Almost Double the S&P 500’s Year-to-Date Gain

    As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date).

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Abbott Laboratories Stock Trades at Its 52-Week High in September

    On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Thermo Fisher to Offer Complete Cannabis Testing Solutions

    Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.

    By Mike Benson
  • uploads///chemist _
    Company & Industry Overviews

    How Thermo Fisher Scientific’s Valuation Looks in September

    Thermo Fisher Scientific currently trades at a forward PE multiple of ~19.9x.

    By Mike Benson
  • uploads///TFX
    Company & Industry Overviews

    Analysts Still Bullish on Teleflex Stock

    Teleflex’s (TFX) interest expenses increased from $19.89 million in the second quarter of 2017 to $26.65 million in the second quarter of 2018.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Expect for Abiomed

    Wall Street analysts estimate Abiomed (ABMD) will report 29.9% growth in revenues to ~$771.0 million in 2019 as compared to $593.7 million in 2018.

    By Mike Benson
  • uploads///hand _
    Company & Industry Overviews

    Do Abiomed’s Valuations Look Attractive?

    Abiomed’s (ABMD) revenues rose 36% YoY to ~$180 million in fiscal Q1 2019 compared to $133 million in Q1 2018.

    By Mike Benson
  • uploads///analysis _
    Company & Industry Overviews

    How Analysts View Becton Dickinson in August 2018

    On August 29, Becton Dickinson stock closed at $259.35, which represents a ~0.66% growth from its prior day’s close of $257.65.

    By Daniel Collins
  • uploads///VAR
    Company & Industry Overviews

    Here’s What Varian Medical Systems’ Valuation Trend Indicates

    Of the nine analysts covering Varian Medical Systems (VAR) stock, three have given it a “strong buy,” three have given it a “hold,” and three have given it a “sell.”

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018

    GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products.

    By Mike Benson
  • uploads///blood _
    Earnings Report

    What Analysts Expect from Haemonetics in Q1 2019

    Haemonetics is expected to report 4.3% growth in revenues to $219.9 million during Q1 2019 as compared to $210.9 million during Q1 2018.

    By Mike Benson
  • uploads///checklist _
    Earnings Report

    How Baxter International Fared in the Second Quarter

    Baxter’s gross profit increased from $1.13 billion in Q2 2017 to $1.24 billion in Q2 2018.

    By Kenneth Smith
  • uploads///cryoablation
    Company & Industry Overviews

    Assessing BSX’s Recently Acquired Cryterion Cryoablation Platform

    On July 5, Boston Scientific announced its acquisition of Cryterion Medical, which will add Cryterion’s cryoablation platform to BSX’s atrial fibrillation treatment portfolio.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Commercial Launch of NexSys PCS May Boost Haemonetics’s Revenues

    Haemonetics is also involved in plasma donor center experience programs that involve the use of NexSys PCS device and YES technology.

    By Margaret Patrick
  • uploads///healthcre
    Healthcare

    How the Healthcare Sector’s Dividend Yield Stacks Up

    The healthcare industry has an average dividend yield of 1.9%.

    By Amanda Lawrence
  • uploads///mitraclip
    Company & Industry Overviews

    MitraClip Drives Growth, Gets Reimbursement Approval in Japan

    On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    The Hospital Business Remains 1of HAE’s Key Growth Drivers

    In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $46.7 million in its hospital business, a YoY (year-over-year) rise of ~9.1%.

    By Margaret Patrick
  • uploads///VALUE BASED SYSTEM
    Company & Industry Overviews

    Medtronic’s New Partnership to Deliver Value-Based Healthcare

    On February 28, 2018, Medtronic (MDT) announced that it has entered into a partnership with LVHN (Lehigh Valley Health Network), an eight-hospital network.

    By Sarah Collins
  • uploads///RESOLUTE ONYX
    Company & Industry Overviews

    Medtronic Launches Its Resolute Onyx 2.0 mm DES

    On February 26, 2018, Medtronic (MDT) announced that the FDA has approved the launch of its Resolute Onyx 2.0 mm DES.

    By Sarah Collins
  • uploads///GUARDIAN SENSOR
    Company & Industry Overviews

    FDA Approves Arm Indication for Medtronic’s Guardian Sensor 3

    On February 26, 2018, Medtronic (MDT) announced that the FDA has approved a new arm indication for its Guardian Sensor 3.

    By Sarah Collins
  • uploads///MINIMED MIO
    Company & Industry Overviews

    Medtronic Strengthens Diabetes Business with MiniMed Infusion Set

    On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    What’s Abbott Laboratories’ Current Valuation?

    As of March 7, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 20.8x, while the stock has a PE ratio of 59x.

    By Sarah Collins
  • uploads///masters hp
    Company & Industry Overviews

    ABT Gets FDA Approval for World’s Smallest Mechanical Heart Valve

    Abbott announced that it received FDA approval for its Masters HP 15-mm rotatable mechanical heart valve, which is the first and only heart valve developed for newborns and infants.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    BSX Stock Rises More Than 2% Following EMcision Acquisition

    Boston Scientific’s recent stock performance On March 6, 2018, Boston Scientific (BSX) stock closed at $27.41, higher than its 50-day moving average of $27.15 and lower than its 200-day moving average of $27.52. As of March 7, 2018, Boston Scientific’s 52-week high was $29.93 on October 23, 2017, and its 52-week low was $24.02 on March 22, 2017. Factors […]

    By Sarah Collins
  • Market Realist Logo

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.